Available Trials

Advanced/Metastatic Malignancies

  • USO 16041

    An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational

    Available at 6 locations

Breast Cancer

  • STAR 16010

    A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer

    Available at 1 location

  • USOR 17082

    A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

    Available at 7 locations

  • USOR 17009

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxal plus a Reduced Dose of Capecitabine vs Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with Taxane

    Available at 7 locations

  • STAR 16195

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Available at 1 location

  • USOR 16023

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Recieved at Least Two Prior Treatments (IMMU-132-05)

    Available at 7 locations

  • USOR 16128

    Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

    Available at 5 locations

  • Alliance NSABP B-57-I

    Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Available at 1 location

Head and Neck

  • USOR 17132

    A PHASE III, MULTICENTER, RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

    Available at 7 locations

Hematologic

  • USOR 16092

    Prospective, Longitudinal, Non-Interventional, Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocytemia (ET) or ET Patients Recieving ET-Directed Therapy (MOST)

    Available at 7 locations

  • MDS/AML OBSERVATIONAL STUDY

    Connect MDS and AML Disease registry

    Available at 6 locations

Leukemia

  • AZA-MDS-006

    The myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

    Available at 2 locations

Lung Cancer

  • STAR 15079

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours

    Available at 8 locations

  • USOR 17201

    A Randomized Phase 2 Trial of AM0010 in Combination with Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects with Stage IV/Metastatic WIld Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

    Available at 6 locations

  • USOR 17199

    A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line (1L) Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expressoin

    Available at 6 locations

  • USOR 17076

    A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

    Available at 4 locations

  • USOR 16156

    A phase IIIB/IV Safety Tiral of Flat Dose Nivolumab in Combination with Ipilimuab in Participants with Non-Small Cell Lung Cancer

    Available at 7 locations

  • LUNG USO 16156

    A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with NSCLC

    Available at 6 locations

Lymphoma

  • STAR 16248

    An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects with Advanced Solid Tumors or with B Cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with Diffuse Large B Cell Lymphoma

    Available at 8 locations

  • STAR 11282

    A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodkin Lymphoma (HL) in Adults Age 60 and Above

    Available at 8 locations

  • STAR 13092

    A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA

    Available at 1 location

  • USOR 16065

    A Phase 2b Randomized Study to Assess the Efficacy and Safety of Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

    Available at 5 locations

  • LYMPHOMA USO 16065

    A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (UTX-TGR-205)

    Available at 6 locations

Multiple Myeloma

  • USOR 16035

    A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients

    Available at 7 locations

  • MULTIPLE MYELOMA USO 16035

    global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study – start Nov2016

    Available at 6 locations

Myelofibrosis

  • STAR 17085

    An Open-Label Phase 2 Study of Itacitinib (INCB09110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis

    Available at 8 locations

Ovarian Cancer

  • USOR 16233

    A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

    Available at 5 locations

Prostate Cancer

  • STAR 16238

    A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

  • USOR 16237

    A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

  • USOR 17149

    A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer

    Available at 4 locations

  • USOR 16160

    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS

    Available at 5 locations

Renal Cancer

  • USOR 16145

    A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma

    Available at 7 locations

Skin Cancer

  • STAR 17060

    A Phase II, Open-Labeled, Single Arm Study to Evaluate Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

    Available at 8 locations

Solid Tumors

  • STAR 16248

    An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects with Advanced Solid Tumors or with B Cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with Diffuse Large B Cell Lymphoma

    Available at 8 locations

  • USOR 16041

    An Open-label Phase 2 Multi-Cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

    Available at 5 locations

  • USOR 17063

    A Phase 1 Dose Escalation and Cohor Expansion Study of TSR-022, and anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    Available at 1 location

  • USOR 17038

    A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

    Available at 1 location

  • USOR 16140

    The Circulating Cell-free Genome Atlas Study (GRAIL)

    Available at 7 locations

Rare Malignancies

  • USOR 16041

    An Open-label Phase 2 Multi-Cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

    Available at 5 locations

Urothelial Cancer

  • USOR 17165

    Phase 1b/2 Study to Evaluate Safety,Efficacy, Pharmacokinetics and Pharmacodnamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations

    Available at 1 location

  • USOR 17005

    A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG - 22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Recieved Immune Checkpoint Inhibitor (CPI) Therapy

    Available at 7 locations